You’re quoting the 10K about holding off on fabrication of Flaskworks units. That refers to commercial rollout, not regulatory readiness. MHRA does not require production lines to be live. It requires the system to be validated and properly included in the dossier. Flaskworks met that standard
If Flaskworks was part of a variation then that variation was submitted during an active MAA review because that is the only time you can file one. Variations are not substitutes for full applications. They are adjustments or additions to a submission that is already on file and being reviewed
A variation confirms two things. The MAA is real and under review. And the company is actively engaging with MHRA, not passively waiting. That is not a negative. It signals alignment, not delay
You are trying to turn the concept of a variation into a weakness when it is the opposite. At this point in the process the only viable reasons to file one are to clarify delivery, update manufacturing, expand the label, or move toward a tissue agnostic indication. None of that undermines the review. It strengthens it
Even your own group is splitting over this. Some of them realized what you did not. A variation this late in the process is confirmation the file is real, the process is active, and the company may be pushing for more than originally expected
You walked it in yourself. Whether you realized it or not
Bullish
Market Data 
Markets 
AI
